We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo's SpHb Hemoglobin Monitoring Study Results Positive
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) recently announced favorable results from a study, which evaluated the performance of noninvasive hemodynamic monitoring (NIHM) using Masimo noninvasive and continuous hemoglobin (SpHb). Masimo’s share price rallied 0.8% to $84.62 on Feb 23 post the announcement of the results.
Notably, SpHb monitoring offers real-time visibility to changes or lack of changes in hemoglobin in blood samples, without which clinicians often get limited access to invasive methods, delaying laboratory results.
Conducted at Michigan State University, a comparison was drawn with invasive laboratory hemoglobin (LabHb) monitoring on trauma patients having solid organ injury with severity score of 16.6. Their status of blood flow was assessed using physical examination per normal institutional pediatric trauma guidelines.
NIHM using Masimo SpHb was conducted continuously using a Masimo Radical-7 Pulse CO-Oximeter and SpHb values were recorded multiple times to correspond with LabHb blood draws.
Study results reflect NIHM’s (using Masimo SpHb) clinically acceptable precision, while following hemoglobin trends in the defined pediatric trend patient population. Researchers have further deduced that NIHM is a valuable addition to traditional laboratory hemoglobin monitoring.
Market Prospects
Per forecasts made by Research and Markets, the global hemoglobin testing market is projected to see a CAGR of 10.6% between 2016 and 2020.
The gradual shift from traditional POCT (Point of Care Testing) methods in laboratories boosts the market.
Consequently, the proven study results of Masimo’s SpHb are likely to fortify the company’s hold in the niche of hemoglobin monitoring, apart from driving the customer base.
Price Performance
In the past year, Masimo has underperformed the industry in terms of price. The stock has lost 6.2% against the industry’s rally of 24%.
Zacks Rank & Key Picks
Masimo carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are athenahealth Inc. , Express Scripts Holding Company and Bioverativ Inc. . Each of the stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealth has an expected long-term growth rate of 20.7%. In the past three months, the stock has gained 8%.
Express Scripts has a projected long-term growth rate of 10%. In the past six months, the stock has returned 25.9%.
Bioverativ has an expected long-term growth rate of 14%. In the past six months, the stock has returned 85.5%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Masimo's SpHb Hemoglobin Monitoring Study Results Positive
Masimo Corporation (MASI - Free Report) recently announced favorable results from a study, which evaluated the performance of noninvasive hemodynamic monitoring (NIHM) using Masimo noninvasive and continuous hemoglobin (SpHb). Masimo’s share price rallied 0.8% to $84.62 on Feb 23 post the announcement of the results.
Notably, SpHb monitoring offers real-time visibility to changes or lack of changes in hemoglobin in blood samples, without which clinicians often get limited access to invasive methods, delaying laboratory results.
Conducted at Michigan State University, a comparison was drawn with invasive laboratory hemoglobin (LabHb) monitoring on trauma patients having solid organ injury with severity score of 16.6. Their status of blood flow was assessed using physical examination per normal institutional pediatric trauma guidelines.
Masimo Corporation Price and Consensus
Masimo Corporation Price and Consensus | Masimo Corporation Quote
NIHM using Masimo SpHb was conducted continuously using a Masimo Radical-7 Pulse CO-Oximeter and SpHb values were recorded multiple times to correspond with LabHb blood draws.
Study results reflect NIHM’s (using Masimo SpHb) clinically acceptable precision, while following hemoglobin trends in the defined pediatric trend patient population. Researchers have further deduced that NIHM is a valuable addition to traditional laboratory hemoglobin monitoring.
Market Prospects
Per forecasts made by Research and Markets, the global hemoglobin testing market is projected to see a CAGR of 10.6% between 2016 and 2020.
The gradual shift from traditional POCT (Point of Care Testing) methods in laboratories boosts the market.
Consequently, the proven study results of Masimo’s SpHb are likely to fortify the company’s hold in the niche of hemoglobin monitoring, apart from driving the customer base.
Price Performance
In the past year, Masimo has underperformed the industry in terms of price. The stock has lost 6.2% against the industry’s rally of 24%.
Zacks Rank & Key Picks
Masimo carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are athenahealth Inc. , Express Scripts Holding Company and Bioverativ Inc. . Each of the stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealth has an expected long-term growth rate of 20.7%. In the past three months, the stock has gained 8%.
Express Scripts has a projected long-term growth rate of 10%. In the past six months, the stock has returned 25.9%.
Bioverativ has an expected long-term growth rate of 14%. In the past six months, the stock has returned 85.5%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>